" class="no-js "lang="en-US"> Vincenza Nigro - Medtech Alert
Wednesday, September 17, 2025
Vincenza Nigro

Vincenza Nigro

About Vincenza Nigro

As a Pharma Executive, I specialize in strategy development and commercialization of innovative therapies for biotech and global companies (Roche).

I trained as a scientist before moving through the ranks of clinical development, medical affairs and commercial. The combination of experience across the pharma continuum translates into diverse leadership and sense-making/giving skills leading to novel insights and solutions.

I bring versatility and life cycle management expertise in the US and globally in Hematology/Oncology, Transplantation and Infectious Diseases (rare/orphan and general population diseases).

Related Story

Hansa Biopharma Announces First Patient Treated in the Post-authorization Efficacy Study (PAES) of Idefirix® (Imlifidase) in Highly Sensitized Kidney Transplant Patients

July 11 2022

Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare immunological conditions, […]